Rybin Vitalyi O, Guo Jianfen, Gertsberg Zoya, Feinmark Steven J, Steinberg Susan F
Department of Pharmacology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
J Biol Chem. 2008 Jun 27;283(26):17777-88. doi: 10.1074/jbc.M800333200. Epub 2008 Apr 3.
Protein kinase Cdelta (PKCdelta) activation is generally attributed to lipid cofactor-dependent allosteric activation mechanisms at membranes. However, recent studies indicate that PKCdelta also is dynamically regulated through tyrosine phosphorylation in H(2)O(2)- and phorbol 12-myristate 13-acetate (PMA)-treated cardiomyocytes. H(2)O(2) activates Src and related Src-family kinases (SFKs), which function as dual PKCdelta-Tyr(311) and -Tyr(332) kinases in vitro and contribute to H(2)O(2)-dependent PKCdelta-Tyr(311)/Tyr(332) phosphorylation in cardiomyocytes and in mouse embryo fibroblasts. H(2)O(2)-dependent PKCdelta-Tyr(311)/Tyr(332) phosphorylation is defective in SYF cells (deficient in SFKs) and restored by Src re-expression. PMA also promotes PKCdelta-Tyr(311) phosphorylation, but this is not associated with SFK activation or PKCdelta-Tyr(332) phosphorylation. Rather, PMA increases PKCdelta-Tyr(311) phosphorylation by delivering PKCdelta to SFK-enriched caveolae. Cyclodextrin treatment disrupts caveolae and blocks PMA-dependent PKCdelta-Tyr(311) phosphorylation, without blocking H(2)O(2)-dependent PKCdelta-Tyr(311) phosphorylation. The enzyme that acts as a PKCdelta-Tyr(311) kinase without increasing PKCdelta phosphorylation at Tyr(332) in PMA-treated cardiomyocytes is uncertain. Although in vitro kinase assays implicate c-Abl as a selective PKCdelta-Tyr(311) kinase, PMA-dependent PKCdelta-Tyr(311) phosphorylation persists in cardiomyocytes treated with the c-Abl inhibitor ST1571 and c-Abl is not detected in caveolae; these results effectively exclude a c-Abl-dependent process. Finally, we show that 1,2-dioleoyl-sn-glycerol mimics the effect of PMA to drive PKCdelta to caveolae and increase PKCdelta-Tyr(311) phosphorylation, whereas G protein-coupled receptor agonists such as norepinephrine and endothelin-1 do not. These results suggest that norepinephrine and endothelin-1 increase 1,2-dioleoyl-sn-glycerol accumulation and activate PKCdelta exclusively in non-caveolae membranes. Collectively, these results identify stimulus-specific PKCdelta localization and tyrosine phosphorylation mechanisms that could be targeted for therapeutic advantage.
蛋白激酶Cδ(PKCδ)的激活通常归因于膜上脂质辅因子依赖性的变构激活机制。然而,最近的研究表明,在过氧化氢(H₂O₂)和佛波酯12 - 肉豆蔻酸酯13 - 乙酸酯(PMA)处理的心肌细胞中,PKCδ也通过酪氨酸磷酸化受到动态调节。H₂O₂激活Src及相关的Src家族激酶(SFKs),这些激酶在体外作为双功能PKCδ - Tyr(311)和 - Tyr(332)激酶起作用,并在心肌细胞和小鼠胚胎成纤维细胞中促进H₂O₂依赖性的PKCδ - Tyr(311)/Tyr(332)磷酸化。H₂O₂依赖性的PKCδ - Tyr(311)/Tyr(332)磷酸化在SYF细胞(缺乏SFKs)中存在缺陷,并通过Src的重新表达得以恢复。PMA也促进PKCδ - Tyr(311)磷酸化,但这与SFK激活或PKCδ - Tyr(332)磷酸化无关。相反,PMA通过将PKCδ转运至富含SFK的小窝来增加PKCδ - Tyr(311)磷酸化。环糊精处理破坏小窝并阻断PMA依赖性的PKCδ - Tyr(311)磷酸化,但不阻断H₂O₂依赖性的PKCδ - Tyr(311)磷酸化。在PMA处理的心肌细胞中,作为PKCδ - Tyr(311)激酶但不增加PKCδ Tyr(332)磷酸化的酶尚不确定。尽管体外激酶分析表明c - Abl是选择性的PKCδ - Tyr(311)激酶,但在使用c - Abl抑制剂ST1571处理的心肌细胞中,PMA依赖性的PKCδ - Tyr(311)磷酸化仍然存在,并且在小窝中未检测到c - Abl;这些结果有效地排除了c - Abl依赖性过程。最后,我们表明1,2 - 二油酰 - sn -甘油模拟PMA的作用,将PKCδ驱动至小窝并增加PKCδ - Tyr(311)磷酸化,而去甲肾上腺素和内皮素 - 1等G蛋白偶联受体激动剂则不然。这些结果表明,去甲肾上腺素和内皮素 - 1增加1,2 - 二油酰 - sn -甘油的积累,并仅在非小窝膜中激活PKCδ。总的来说,这些结果确定了刺激特异性的PKCδ定位和酪氨酸磷酸化机制,这些机制可能成为治疗靶点以获得治疗优势。